VYNE Therapeutics Inc. (VYNE): Nasdaq/NYSE listing notice — VYNE receives Nasdaq extension to Sept 7, 2026 to regain $1 bid price compliance

VYNE Therapeutics Inc.

Company failed to regain minimum $1.00 bid price by original March 10, 2026 deadline.
Nasdaq granted additional 180 calendar days, until September 7, 2026, to cure deficiency.
VYNE may consider a reverse stock split to meet the bid price requirement.
Common stock continues trading on Nasdaq Capital Market under symbol VYNE during extension.

item 3.01

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.99

VYNE Therapeutics Inc. received a nasdaq extension granted notice regarding minimum bid price (rules 5550(a)(2)).

Exchange: nasdaq
Notice: extension granted
Deficiency: minimum bid price
Rules: 5550(a)(2)

Exact text from the filing

March 11, 2026, the Company received a letter (the “Extension Notice”) from Nasdaq notifying the Company that its request for an extension to regain compliance with the minimum bid price requirement has been granted, and the Company has an additional 180 calendar days, or until September 7, 2026, to regain compliance with the minimum bid price requirement. Nasdaq’s determination was based on the Company meeting the continued listing requirement for market value of publicly held shares and all other applicable requirements for initial listing on the Nasdaq Capital Market with the exception of t

View on SEC.gov

5 listing & compliance notices filed in the last 30 days. Browse all listing & compliance notices →

VYNE Therapeutics Inc. filing history →

Source: SEC EDGAR

accession 0001104659-26-026439

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.